Breaking News
Investing Pro 0
Extended Sale! Save on premium data with Claim 60% OFF

Cigarette maker Philip Morris to buy UK producer of respiratory treatments

Published Jul 09, 2021 02:45AM ET Updated Jul 09, 2021 12:56PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. Philip Morris International Operation Center is pictured in Lausanne August 19, 2009. Philip Morris International (PMI) is the leading international tobacco company, with products sold in approximately 160 countries. REUTERS/Denis Balibouse/Files 2/2
 
BATS
-8.36%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PM
-1.58%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MO
-2.76%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GSK
-0.01%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
CG
+0.81%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BTI
-8.80%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Yadarisa Shabong and Siddharth Cavale

(Reuters) -Tobacco group Philip Morris International (NYSE:PM) agreed on Friday to buy Vectura for 1.05 billions pounds ($1.44 billion), giving the U.S. firm access to the British drugmaker's respiratory ailment treatments and inhaling device technology.

The move by Philip Morris is the latest push by big tobacco companies to change their image following years of negative press and lawsuits for marketing and selling cigarettes, a product that health advocates and experts say continues to be a leading cause of preventable deaths worldwide.

The offer of 150 pence per share to investors in Vectura topped a previous 136 pence proposal by investment firm Carlyle Group (NASDAQ:CG), and was 11% higher than the drugmaker's closing share price on Thursday.

Vectura, whose shares rose as much as 14% to 154 pence, said it was withdrawing its recommendation for Carlyle's proposal and was adjourning a shareholder meeting it had convened on Monday.

Philip Morris aims to use Vectura's expertise with inhalable formulations and device design to produce a range of over-the-counter and prescription-based respiratory therapies, it said in a statement.

It has set a target to generate more than 50% of its revenue from smoke-free products and at least $1 billion from products beyond nicotine by 2025 as part of its "evolution into a broader healthcare and wellness company".

Vectura makes approved inhaled medicines and associated devices to treat respiratory illnesses such as asthma, and counts Novartis AG and GlaxoSmithKline (NYSE:GSK) Plc among its customers.

"On the one hand Phillip Morris’ determination to accelerate the end of smoking might seem like turkeys voting for Christmas but as more and more people shift to 'healthier' lifestyles they would have eventually found themselves obsolete," AJ Bell financial analyst Danni Hewson said.

"The move to scoop up Vectura from under the nose of Carlyle is part of a carefully thought out shift to smoke free products and investing in devices that will make lives better for people suffering from respiratory problems and gives good PR."

BIDDING WAR

Carlyle said it was "considering its options and a further announcement will be made in due course", raising the prospect of a bidding war. In the meantime, it encouraged Vectura shareholders to take no action.

Peel Hunt analysts said Philip Morris' bid underscored the value of Vectura's technology platform, reducing the likelihood of a counter bid by private equity.

Other tobacco majors British American Tobacco (NYSE:BTI) (BAT (LON:BATS)) and Altria have also set ambitious targets to switch customers from smoking to less harmful e-cigarettes, cannabis and tobacco-heating products but with varying degrees of success.

While BAT is seeing a benefit from more smokers switching to its e-cigarettes, Altria Group (NYSE:MO) has seen its $12.8 billion investment in e-cigarette maker Juul Labs nosedive after regulators started taking a much harder stance on vaping products. Altria on Friday also announced it was selling its wine business.

Winston cigarette maker Imperial Brands (OTC:IMBBY) Plc, in contrast, has scaled down its ambitions with vaping devices and other alternative nicotine products, and is doubling down on cigarettes as it embarks on a five-year turnaround plan.

The deal is Philip Morris' second acquisition in the past week, after agreeing to buy nicotine gum maker Fertin Pharma for 5.1 billion Danish Krone ($812 million).

The U.S. company said Vectura will operate as an independent unit and will be the backbone of its inhaled therapeutics unit.

($1 = 0.7264 pounds)

($1 = 6.2842 Danish crowns)

Cigarette maker Philip Morris to buy UK producer of respiratory treatments
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Kaveh Sun
Kaveh Sun Jul 09, 2021 10:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nice, we sell u products to cause u to have breathing problems. We also sell u products to fix that.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email